XRAY Heads Into Earnings With Shorts Rebuilding and Options Turning Cautious

XRAY reports Q2 results on August 3 with short interest near a 30-day high, options positioning the most defensive it has been in weeks, and a Street that remains firmly on the fence.

The most striking development in the positioning data is how quickly shorts have rebuilt. Short interest now stands at 14.6% of the free float — up 34% over the past month alone, from roughly 21.4 million shares in mid-June to 29.2 million today. That is the dominant tension heading into next week's print. The week-on-week rise is more modest at 2.6%, suggesting the bulk of the build happened earlier in July and has since stabilised, but at nearly 15% of float the overall level remains elevated. Official FINRA data put short shares at 29.9 million with a days-to-cover of 5.95, broadly confirming the picture.

The borrow market, however, is far from stressed. Availability is running at around 500% — meaning there are roughly five shares available to borrow for every one already out on loan, well above the 52-week trough of 356% hit on July 10. Cost to borrow ticked up 15% on the week to 0.53%, but in absolute terms that is close to zero. There is no squeeze mechanics here: shorts can add, reduce, or hold positions without meaningful friction. What the lending market tells you is that the short thesis is deliberate and structural rather than a crowded trade under pressure.

Options tell a more defensive story than the lending market alone would suggest. The put/call ratio jumped to 0.57 on July 28, nearly 1.7 standard deviations above its 20-day average of 0.48. That is not an extreme reading — the 52-week high is 1.21 — but the direction of travel is clear: the ratio was sitting comfortably below 0.44 as recently as July 7 and has climbed steadily since. Protective put buying has picked up just as the earnings date approaches, a pattern consistent with investors wanting downside insurance rather than directional conviction either way.

The Street's posture reinforces that ambivalence. The consensus is a hold, with 13 analysts lined up at neutral and a mean price target of $13.38 — almost exactly where the stock is trading at $13.49. Piper Sandler raised its target today from $13 to $14 while keeping a Neutral rating, the most recent move. BMO initiated at Market Perform with a $12 target earlier this month. Barclays sits at Underweight with a $9 target, making it the clearest bear. UBS holds the lone Buy with a $17 target. The bull case rests on restructuring progress and improving U.S. operational trends; the bear case centres on repeated management turnover, declining revenue visibility, and a reduced profitability outlook for FY26. Valuation multiples have moved in the stock's favour over the past month — the P/E has expanded by 1.7 turns to 9.0x, and price-to-book is up roughly 24% to 1.83x — reflecting the 22% one-month price rally, but those multiples also cap the upside argument at current levels given the earnings uncertainty.

Institutional ownership data adds one genuinely interesting wrinkle. BlackRock reported a 6 million share addition as of June 30, pushing its stake to 12.6% and making it the largest holder by some distance. The move is fresh enough to be meaningful. Meanwhile, a cluster of board-level directors bought shares in early-to-mid June at prices between $9.88 and $10.15 — well below today's $13.49. Net insider buying over the past 90 days totals around $659,000 across six directors. Insiders were buying at a 25–35% discount to the current price; whether that conviction was well-timed or whether the subsequent rally has already priced in the improvement is precisely what the August 3 print will test.

The last two earnings reactions for XRAY show modest negative moves — down 0.5% and down 3.8% on the day — both followed by mixed five-day drifts. That history sets a low bar for a dramatic post-earnings reaction, but with short interest elevated, options defensively positioned, and a tight analyst cluster around fair value, the next number to watch is whether Q2 results give the bear thesis — or the board's June buying — the stronger vindication.